Welcome to our dedicated page for Spruce Biosciences SEC filings (Ticker: SPRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spruce Biosciences, Inc. (SPRB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, and its filings offer detailed insight into clinical programs, financing arrangements, and corporate governance.
Investors can review current reports on Form 8-K that describe material events such as the company’s loan and security agreement with Avenue Venture Opportunities Fund II, L.P. for up to $50.0 million in term loans tied to regulatory and commercial milestones for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). Other 8-K filings cover a private placement of common stock and pre-funded warrants with institutional investors, conditional Nasdaq approval and resumption of trading on the Nasdaq Capital Market, reverse stock split implementation, quarterly financial results, and changes in the composition of the board of directors.
Spruce’s filings also detail equity and compensation structures, including option repricing actions for certain outstanding stock options and the non-employee director compensation policy under which new directors such as Keli Walbert receive stock option grants and cash retainers. These documents help clarify how the company uses equity incentives and capital structure adjustments to support its development and listing objectives.
Through this page, you can monitor Spruce’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) when filed, which expand on risk factors, financial statements, and management’s discussion of operations. Form 4 and related insider transaction reports, when available, can be used to track trading activity by officers and directors. Stock Titan’s AI tools summarize lengthy filings, highlight key terms in financing agreements, and surface important disclosures related to TA-ERT’s development path, Nasdaq listing status, and the company’s liquidity and capital resources.
Spruce Biosciences (SPRB) reported Q3 2025 results marked by tighter spending, liquidity strain, and key program milestones. The company posted a net loss of $8.2 million for the quarter and $24.3 million year‑to‑date, with no collaboration revenue recognized in 2025. Operating expenses fell to $8.2 million in Q3 (from $10.0 million a year ago) as R&D declined on program discontinuations and a 55% workforce reduction, partly offset by increased TA‑ERT manufacturing.
Cash and cash equivalents were $10.7 million at September 30, 2025, and the filing states “substantial doubt” about the ability to continue as a going concern. After quarter‑end, Spruce raised approximately $50.0 million in gross proceeds via a private placement and subsequently terminated and repaid its SVB term loan, including the $0.3 million supplemental final payment. The company effected a 1‑for‑75 reverse stock split and relisted on Nasdaq. Development shifted to tralesinidase alfa (TA‑ERT) for MPS IIIB, which received FDA Breakthrough Therapy designation in October 2025, with a planned BLA submission in the first quarter of 2026.
Spruce Biosciences, Inc. filed a current report stating that it has released its financial results for the third quarter ended September 30, 2025. The company announced these results, along with corporate updates, in a press release dated November 10, 2025.
The press release is included as Exhibit 99.1 and is furnished, rather than filed, which means it is not automatically incorporated into other securities law filings unless specifically referenced.
Spruce Biosciences, Inc. filed an S-3 registering up to 735,325 shares for resale by selling stockholders, consisting of 502,181 outstanding shares and 233,144 shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from stockholder sales; it would receive only the $0.01 per share exercise price if any pre-funded warrants are exercised for cash.
The shares relate to a private placement that closed on October 9, 2025. The resale may occur from time to time in public or private transactions at market or negotiated prices as described under “Plan of Distribution.” Including two holder examples shown: ExodusPoint Partners Master Fund, LP 144,580; Citadel CEMF Investments Ltd. 110,000. Shares outstanding were 1,065,672 as of October 10, 2025.
The pre-funded warrants are exercisable at any time, subject to a beneficial ownership limitation of 4.99% or 9.99% (holder election), with a maximum increase upon 60 days’ notice, not above 19.99%.
Spruce Biosciences, Inc. filed an S-3 shelf registration to offer up to $300,000,000 of common stock, preferred stock, debt securities, and warrants, to be sold from time to time in one or more offerings. Terms and amounts for any specific sale will be set in a future prospectus supplement.
The company may sell securities directly, through agents, to/through underwriters or dealers, and may use at-the-market offerings. Net proceeds, if any, will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. Spruce’s common stock trades on the Nasdaq Capital Market under “SPRB”; the last reported price was $124.51 on October 28, 2025.
Spruce completed a one-for-seventy-five reverse stock split effective August 4, 2025; share counts in the prospectus reflect this, including approximately 563,042 shares outstanding as of December 31, 2024.
Spruce Biosciences (SPRB) reported an insider equity event for its President and CFO, Samir Gharib. A performance-based award of 2,053 RSUs granted on March 14, 2024 vested on October 20, 2025 after the board certified performance goals. To cover taxes, 661 shares were withheld at $148.16, resulting in a net issuance of 1,392 shares.
Following these transactions, the officer beneficially owns 6,066 shares, held directly. Each RSU represents the right to receive one share of SPRB common stock upon vesting.
Spruce Biosciences (SPRB) reported an insider equity event by its Chief Executive Officer and director. On 10/20/2025, the Board certified performance goals, causing 4,784 performance‑based RSUs granted on March 14, 2024 to vest. Each RSU represents the right to receive one share of SPRB common stock.
In connection with the vesting, 1,539 shares were withheld for taxes at a price of $148.16, resulting in a net issuance of 3,245 shares. Following these transactions, the reporting person directly beneficially owned 9,474 shares. The Form 4 reflects an “M” code for settlement of RSUs into common stock at $0 and an “F” code for tax withholding.
Spruce Biosciences announced that director Bali Muralidhar, Ph.D. resigned from the board and the compensation committee, effective October 15, 2025. The company stated his departure was not due to any disagreement regarding operations, policies, or practices. This is a governance update with no operational or financial changes disclosed.
Spruce Biosciences (SPRB) — Form 4 insider trading update. Parkman Healthcare Partners LLC and Gregory Martinez reported trades on 10/06/2025 as indirect owners. They purchased 256 shares of common stock at a weighted average price of $17.9108 (within $17.55–$18.00), then sold 232 shares at $19.3264 (within $19.125–$19.63) and sold 25 shares at $17.4557 (within $17.44–$17.56). Following the reported transactions, they beneficially owned 1,050 shares indirectly through private funds. Each reporting person disclaims beneficial ownership beyond pecuniary interest.
Spruce Biosciences (SPRB): Initial insider ownership reported. A Form 3 discloses indirect beneficial ownership of 1,051 shares of common stock. The reporting person is identified as a Director and indicates the shares are held through private funds, with beneficial ownership disclaimed beyond any pecuniary interest.
The filing notes it is made by more than one reporting person, and includes a remark that these securities are also indirectly beneficially owned by Gregory Martinez.
HealthCap VIII amended its Schedule 13D for Spruce Biosciences, Inc. (SPRB) to report current holdings and a recent sale. The filing shows the reporting persons beneficially owned 36,640 shares, equal to 3.4% of Spruce's 1,065,223 outstanding shares after giving effect to warrants exercisable for 9,439 shares. The Fund directly holds 27,201 shares with warrants for 9,439 shares.
On 10/07/2025 the Fund sold 12,500 shares at $205.99 per share. Following these transactions, the reporting persons ceased to be beneficial owners of more than 5% of the common stock as of 10/09/2025. The GP delegates voting and dispositive power to HealthCap Investments S.A., and signatures from HealthCap representatives are included.